The homing ligand targeted to HER-2 overexpression in breast cancer, is the anti-HER-2 mAb, which is mostly conjugated onto NP platforms for the active targeting PS delivery in PDT breast cancer applications [63]. This evidence concerns the gene ERBB2 and breast carcinoma.